Mary Sugrue is an Oncology physician affiliated with Celgene. OpenAlex indexes 62 publications with 2,831 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
2 NIH research awards on record, funded 1997–2007 per NIH RePORTER. The latest:
- Regulation of Irreversible Growth Arrest by p53
Icahn School of Medicine at Mount Sinai
FY2007$229,022R01CA098552 - Regulation of Irreversible Growth Arrest by p53
Icahn School of Medicine at Mount Sinai
FY2006$235,861R01CA098552 - Regulation of Irreversible Growth Arrest by p53
Mount Sinai School of Medicine of Nyu
FY2005$241,538R01CA098552
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”